IONIS PHARMACEUTICALS INC (IONS) research
IONIS PHARMACEUTICALS INC- Sector
- Biotechnology
- Last price
- $44.90
- As of
IONIS PHARMACEUTICALS INC (IONS): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-04.
As of . Source: SEC EDGAR filings for IONS. Method and limitations.
Share the IONS intelligence card
See IONS live in the terminal
Track IONS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live IONS terminal, freeActive signals for IONS
- highCONSENSUS_BUY
5 tracked funds increased IONS this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased IONS this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 76% of IONS (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 73% of IONS (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +83% to IONS (2026Q2)
FREE, NO ACCOUNT
Every signal on IONS, as it fires
You are seeing 5 of 38 signals recorded on IONS since 2026-05-29.
The five above landed across 2 days. The other 33 were recorded on 4 other days. 30 of the 38 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IONS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 462222100 · 2026Q2 | $495.7M | 0.36% | , |
| CITADEL ADVISORS LLCCUSIP 462222AF7 · 2026Q2 | $134.7M | 0.02% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 462222100 · 2026Q2 | $44.4M | 0.06% | , |
| D. E. Shaw & Co., Inc.CUSIP 462222100 · 2026Q2 | $23.6M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 462222100 · 2026Q2 | $22.9M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 462222100 · 2026Q2 | $18.7M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IONS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IONS mentioned in Kresmion daily briefs
IONS against its peers
IONS's operating margin of -40.4% ranks in the 57th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | IONS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 944M USD | 88.0M USD | 92 | 17 |
| Operating margin | -40.4% | -163.6% | 57 | 14 |
| Net margin | -40.4% | -193.2% | 57 | 14 |
| Return on equity | -78.0% | -22.3% | 11 | 22 |
Peers (24): IMVT, RYTM, ALKS, BLTE, CAI, SYRE, TGTX, CGON, PRAX, SRRK, ABVX, MIRM, CNTA, PCVX, IBRX, CRNX, ORKA, TVTX, KYMR, PTGX, COGT, CYTK, LGND, NUVL. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (IONS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more IONS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to IONSand get the insider, 13F, options, and confluence read in one view.